Notwithstanding the lack of conclusive clinical investigation of anti-IgE strategies in SLE, research on modulating pDCs to reduce IFN signatures increased by IgE complexes is especially relevant for SLE (259, 286, 287). The gene discussed is IGHE; the disease is systemic lupus erythematosus.